Clinical Hematology International
Volume 2, Issue 1, March 2020
Editorial
1. Looking Ahead: Clinical Hematology International Turns One
Mohamad Mohty, Arnon Nagler, Bipin Savani
Pages: 1 - 1
Perspective
2. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation
Abraham S. Kanate, Arnon Nagler, Bipin Savani
Pages: 2 - 4
Due to the increasingly strict word/character restrictions enforced by most scientific publications, we identified a need for a master document illustrating the “Scientific Methods” that may be applicable to the majority of observational and registry-based studies in hematopoietic cell transplantation...
Review Article
3. Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults
Cosmin Tegla, Jun Choi, Maher Abdul-Hay, Frank Cirrone, Kelli Cole, A Samer Al-Homsi
Pages: 5 - 12
Graft-versus-host disease (GvHD) in its acute and chronic forms continues to represent a significant barrier to the success and wide-applicability of blood and marrow transplantation as a potentially curative treatment modality for a number of benign and malignant blood conditions. Presently, calcineurin...
Review Article
4. Emerging Therapies for the Myelodysplastic Syndromes
Jonathan Canaani
Pages: 13 - 17
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the diverse...
Review Article
5. Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells
Oluwadunni E. Emiloju, Rashmika Potdar, Vinicius Jorge, Sorab Gupta, Gabor Varadi
Pages: 18 - 26
Apart from peripheral blood stem cell (PBSC), umbilical cord blood (UCB) is now a recognized source of stem cells for transplantation. UCB is an especially important source of stem cells for minority populations, which would otherwise be unable to find appropriately matched adult donors. UCB has fewer...
Research Article
6. Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Bogdan Popescu, Sheenu Sheela, Julie Thompson, Sophia Grasmeder, Therese Intrater, Christin B. DeStefano, Christopher S. Hourigan, Catherine Lai
Pages: 27 - 31
Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single...
Case Report
7. Human Herpes Virus-6 Encephalitis Following Autologous Blood and Marrow Transplant
Jacques Mario Azzi, Doyun Park, Maher Abdul-Hay, Kelli Cole, Frank Cirrone, Maxim Kreditor, A. Samer Al-Homsi
Pages: 32 - 34
Human herpesvirus-6 (HHV-6) is a highly prevalent virus that establishes lifelong latency in human hosts. Symptomatic HHV-6 reactivation rarely occurs in immunocompetent individuals and is best described in immunosuppressed patients such as recipients of bone marrow transplants (BMT). In that setting,...
Correspondence
8. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Kristian T. Andersen, Maja Hinge, Agoston Gyula Szabo, Erik Segel, Tina Ormstrup, Paw C. Holdgaard, Niels Pallisgaard, Gitte Kerndrup, Torben Plesner
Pages: 35 - 39